Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells

Stem Cells

Volumn 27, Issue 1, 2009, Pages 126-137

  Zhang, Zhi Yong ^a   Teoh, Swee Hin ^a   Chong, Mark S K ^a   Schantz, Jan Thorsten ^b   Fisk, Nicholas M ^c   Choolani, Mahesh A ^b   Chan, Jerry ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adipose tissue; Bone marrow; Fetal; Mesenchymal stem cells; Scaffold; Tissue engineering; Umbilical cord

Indexed keywords

ALKALINE PHOSPHATASE; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATE; POLYCAPROLACTONE; TRANSCRIPTION FACTOR NANOG;

ADIPOSE TISSUE; ADULT STEM CELL; ANIMAL EXPERIMENT; ARTICLE; BONE TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS CELL; GENE INDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MONOLAYER CULTURE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; SCANNING ELECTRON MICROSCOPY; TISSUE ENGINEERING; UMBILICAL CORD;

ADIPOSE TISSUE; ADULT; ADULT STEM CELLS; ANIMALS; BONE AND BONES; CALCIUM PHOSPHATES; CELL DIFFERENTIATION; CELL PROLIFERATION; FETUS; GENE EXPRESSION REGULATION; HUMANS; IMPLANTS, EXPERIMENTAL; INFANT; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; MIDDLE AGED; OSTEOGENESIS; POLYESTERS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; UMBILICAL CORD;

MUS;

EID: 59849114318     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0456     Document Type: Article

References (64)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006;1:365-369.
3. Pountos I, Corscadden D, Emery P et al. Mesenchymal stem cell tissue engineering: Techniques for isolation, expansion and application. Injury 2007;38(suppl 4):S23-S33.
4. Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy 2005;7:36-45.
5. Qi H, Aguiar DJ, Williams SM et al. Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. Proc Natl Acad Sci U S A 2003;100:3305-3310.
6. Frank O, Heim M, Jakob M et al. Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro. J Cell Biochem 2002;85:737-746.
7. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997;64:278-294.
8. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
9. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729.
10. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389-397.
11. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
12. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
13. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341-347.
14. Mauney JR, Volloch V, Kaplan DL. Role of adult mesenchymal stem cells in bone tissue engineering applications: Current status and future prospects. Tissue Eng 2005;11:787-802.
15. Niemeyer P, Krause U, Kasten P et al. Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage. Curr Stem Cell Res Ther 2006;1:21-27.
16. Cowan CM, Shi YY, Aalami OO et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol 2004;22:560-567.
17. Meinel L, Betz O, Fajardo R et al. Silk based biomaterials to heal critical sized femur defects. Bone 2006;39:922-931.
18. Petite H, Viateau V, Bensaid W et al. Tissue-engineered bone regeneration. Nat Biotechnol 2000;18:959-963.
19. Phinney DG, Kopen G, Righter W et al. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 1999;75:424-436.
20. Mendes SC, Tibbe JM, Veenhof M et al. Bone tissue-engineered implants using human bone marrow stromal cells: Effect of culture conditions and donor age. Tissue Eng 2002;8:911-920.
21. Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001;82:583-590.
22. D'Ippolito G, Schiller PC, Ricordi C et al. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999;14:1115-1122.
23. Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211-228.
24. Sarugaser R, Lickorish D, Baksh D et al. Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors. STEM CELLS 2005;23:220-229.
25. Bieback K, Kern S, Kluter H et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. STEM CELLS 2004;22:625-634.
26. Lee OK, Kuo TK, Chen W-M et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004;103:1669-1675.
27. De Coppi P, Bartsch G Jr, Siddiqui MM et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25:100-106.
28. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003;102:1548-1549.
29. Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-2402.
30. Chan J, O'Donoghue K, de la Fuente J et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. STEM CELLS 2005;23:93-102.
31. Chan J, O'Donoghue K, Gavina M et al. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. STEM CELLS 2006;24:1879-1891.
32. Chan J, Waddington SN, O'Donoghue K et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. STEM CELLS 2007;25:875-884.
33. Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920-926.
34. Salgado AJ, Coutinho OP, Reis RL. Bone tissue engineering: State of the art and future trends. Macromol Biosci 2004;4:743-765.
35. LeGeros RZ. Properties of osteoconductive biomaterials: Calcium phosphates. Clin Orthop Relat Res 2002:81-98.
36. Rai B, Teoh SH, Hutmacher DW et al. Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials 2005;26:3739-3748.
37. Hutmacher DW, Schantz T, Zein I et al. Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. J Biomed Mater Res 2001;55:203-216.
38. Polkinghorne J. Review of the Guidance on the Research Use of Fetuses and Fetal Material. CM 762. London: HMSO, 1989.
39. Gronthos S, Franklin DM, Leddy HA et al. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001;189:54-63.
40. Guillot PV, Gotherstrom C, Chan J et al. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. STEM CELLS 2007;25:646-654.
41. Rai B, Teoh SH, Ho KH et al. The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds. Biomaterials 2004;25:5499-5506.
42. Bongso A. Stem Cells: From Bench to Bedside. Hackensack, NJ: World Scientific, 2005:442.
43. Boyce T, Edwards J, Scarborough N. Allograft bone. The influence of processing on safety and performance. Orthop Clin North Am 1999;30:571-581.
44. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
45. Loh YH, Wu Q, Chew JL et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006;38:431-440.
46. Kermani AJ, Fathi F, Mowla SJ. Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: Potential application in cell-based gene therapy. Rejuvenation Res 2008;11:379-386.
47. Pochampally RR, Smith JR, Ylostalo J et al. Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. Blood 2004;103:1647-1652.
48. Gotherstrom C. Immunomodulation by multipotent mesenchymal stromal cells. Transplantation 2007;84(1 suppl):S35-S37.
49. Gotherstrom C, Ringden O, Tammik C et al. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004;190:239-245.
50. Gotherstrom C, Ringden O, Westgren M et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265-272.
51. Le Blanc K, Gotherstrom C, Ringden O et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607-1614.
52. Guillot PV, Abass O, Bassett JH et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 2008;111:1717-1725.
53. Gronthos S, Graves SE, Ohta S et al. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood 1994;84:4164-4173.
54. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991;78:55-62.
55. Kim BS, Lee CC, Christensen JE et al. Growth, differentiation, and biochemical signatures of rhesus monkey mesenchymal stem cells. Stem Cells Dev 2008;17:185-198.
56. Guillot PV, De Bari C, Dell'accio F et al. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation 2008; Jun 13 [Epub ahead of print].
57. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. STEM CELLS 2007;25:1384-1392.
58. Abbott A. Cell culture: Biology's new dimension. Nature 2003;424:870-872.
59. Cukierman E, Pankov R, Stevens DR et al. Taking cell-matrix adhesions to the third dimension. Science 2001;294:1708-1712.
60. Grayson WL, Zhao F, Izadpanah R et al. Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol 2006;207:331-339.
61. Im GI, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage 2005;13:845-853.
62. Liu TM, Martina M, Hutmacher DW et al. Identification of common pathways mediating differentiation of bone marrow-and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. STEM CELLS 2007;25:750-760.
63. Panepucci RA, Siufi JL, Silva WA Jr et al. Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. STEM CELLS 2004;22:1263-1278.
64. Rai B, Oest ME, Dupont KM et al. Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair. J Biomed Mater Res A 2007;81:888-899.